Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shane M Devlin

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Canadian Journal of Gastroenterology & Hepatology|May 20, 2014
Defining quality indicators for best-practice management of inflammatory bowel disease in CanadaGeoffrey C Nguyen, Shane M Devlin, Waqqas Afif, et al.
Gastroenterology & Hepatology|October 1, 2011
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupMiles P Sparrow, Peter M Irving, Leonard Baidoo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 6, 2018
Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit AllGil Y Melmed, Gilaad G Kaplan, Miles P Sparrow, et al.
Gastroenterology|January 30, 2007
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relativesShane M Devlin, Huiying Yang, Andrew Ippoliti, et al.
The American Journal of Gastroenterology|July 15, 2024
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel DiseaseHannah K Systrom, Victoria Rai, Siddharth Singh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit allGil Y Melmed, Brennan M Spiegel, Brian Bressler, et al.
Inflammatory Bowel Diseases|April 9, 2016
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness PanelShane M Devlin, Gil Y Melmed, Peter M Irving, et al.
Inflammatory Bowel Diseases|March 23, 2017
Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort StudyChristopher Ma, Richard N Fedorak, Gilaad G Kaplan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 1, 2019
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort StudyHang Hock Shim, Christopher Ma, Paulo G Kotze, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Canadian Journal of Gastroenterology & Hepatology|May 20, 2014
Defining quality indicators for best-practice management of inflammatory bowel disease in CanadaGeoffrey C Nguyen, Shane M Devlin, Waqqas Afif, et al.
Gastroenterology & Hepatology|October 1, 2011
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupMiles P Sparrow, Peter M Irving, Leonard Baidoo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 6, 2018
Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit AllGil Y Melmed, Gilaad G Kaplan, Miles P Sparrow, et al.
Gastroenterology|January 30, 2007
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relativesShane M Devlin, Huiying Yang, Andrew Ippoliti, et al.
The American Journal of Gastroenterology|July 15, 2024
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel DiseaseHannah K Systrom, Victoria Rai, Siddharth Singh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit allGil Y Melmed, Brennan M Spiegel, Brian Bressler, et al.
Inflammatory Bowel Diseases|April 9, 2016
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness PanelShane M Devlin, Gil Y Melmed, Peter M Irving, et al.
Inflammatory Bowel Diseases|March 23, 2017
Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort StudyChristopher Ma, Richard N Fedorak, Gilaad G Kaplan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 1, 2019
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort StudyHang Hock Shim, Christopher Ma, Paulo G Kotze, et al.
Pageof 4